Stephanie van Hoppe

61 Brain accumulation of osimertinib and its active metabolite is restricted by ABCB1 & ABCG2 R E F E R E N C E S 1. Bareschino MA, Schettino C, Rossi A, et al. Treatment of advanced non small cell lung cancer, J Thorac Dis, 2 (2011) 122-133. 10.3978/j.issn.2072-1439.2010.12.08 2. Thippeswamy R, Noronha V, Krishna V, et al. Stage IV lung cancer: Is cure possible?, Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 2 (2013) 121-125. 10.4103/0971-5851.116207 3. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer, Ann Thorac Surg, 1 (1996) 246-250. 4. Mamon HJ, Yeap BY, Janne PA, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation, J Clin Oncol, 7 (2005) 1530-1537. 10.1200/JCO.2005.04.123 5. Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib, Clin Cancer Res, 23 (2010) 5873-5882. 10.1158/1078-0432.CCR-10-1588 6. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System, J Clin Oncol, 14 (2004) 2865-2872. 10.1200/JCO.2004.12.149 7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 25 (2010) 2380-2388. 10.1056/NEJMoa0909530 8. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 3 (2012) 239-246. 10.1016/S1470- 2045(11)70393-X 9. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 27 (2013) 3327-3334. 10.1200/ JCO.2012.44.2806 10. Ramalingam SS, O'Byrne K, Boyer M, et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 3 (2016) 423-429. 10.1093/annonc/mdv593 11. Rossi S, Toschi L, Finocchiaro G, et al. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors, Clin Lung Cancer, (2018) 82-87. 10.1016/j.cllc.2018.10.009 12. Cai Y, Wang X, Guo Y, et al. Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report, Medicine (Baltimore), 1 (2019) e13890. 10.1097/ MD.0000000000013890 13. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 3 (2005) e73. 10.1371/journal. pmed.0020073 14. Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients, Ann Oncol, 10 (2015) 2073-2078. 10.1093/annonc/mdv319 15. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 8 (2005) 786-792. 10.1056/NEJMoa044238 16. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, 9 (2014) 1046-1061. 10.1158 /2159-8290.CD- 14-0337 17. Center for Drug valuation and Research of the U.S., Department of Health and Human Servics Food and Drug Administration, https://wwwfdagov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm605113htm, (2018)